Stocktoria
Raia Drogasil S.A. RADL3.SA
Raia Drogasil S.A. (RADL3.SA) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the grey zone. It does not currently pay a dividend. FY2025 revenue was $44.3B at a 2.9% net margin.
Price from month-end closes (Yahoo) — for reference, not real-time.
How it ranks in Healthcare · percentile among 36 companies
Percentile vs other Healthcare companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | 0.187 |
| Retained earnings / assets | 0.0 |
| EBIT / assets | 0.105 |
| Equity / liabilities | 0.411 |
FAQ
Is RADL3.SA financially healthy?
Raia Drogasil S.A.'s Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does RADL3.SA pay a dividend?
No, Raia Drogasil S.A. does not currently pay a dividend.
How profitable is RADL3.SA?
In FY2025, Raia Drogasil S.A. had a net margin of 2.9% and a return on equity of 17.7%.
Source: company filings via Yahoo Finance · BR · as of 2025-12-31. Figures in BRL; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.